PROFILE Study Version 1.1
Research type
Research Study
Full title
The PROFILE Study- Germline genetic profiling: correlation with targeted prostate cancer screening and treatment.
IRAS ID
132999
Contact name
Rosalind Eeles
Contact email
Sponsor organisation
Institute of Cancer Research
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
16408, Central Portfolio Management System (CPMS); 11931, Cancer Research UK (CRUK) internal database number
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Prostate cancer is the most common cancer in men in the Western world with over 40,000 men diagnosed each year and a lifetime risk of 1 in 11 in the United Kingdom. Prostate cancer can run in some families and research studies have identified several genetic changes that are thought to increase the risk of developing prostate cancer. Additionally, men from Afro-Caribbean ancestry are thought to have an increased risk of prostate cancer when compared to Caucasian men. This study aims to look at the potential risk of these changes in targeted screening in men at a higher genetic risk. Some of these changes may cause a very slight increase in prostate cancer risk while others may cause a much larger increase in risk of developing prostate cancer.
We will invite Caucasian men with a family history of prostate cancer and men who are of African/Afro-Caribbean origin (irrespective of family history) for targeted prostate screening (PSA testing, MRI and a biopsy of the prostate gland) and genetic profiling. Prostate biopsy/MRI are voluntary and will not affect entry into the study.
This research will help us to determine what the risk of cancer is for men who have inherited these genetic changes and/or for men from the Afro-Caribbean origin and also increase our knowledge about the role of genetics and ethnicity in developing prostate cancer.
REC name
London - Riverside Research Ethics Committee
REC reference
13/LO/1787
Date of REC Opinion
21 Jan 2014
REC opinion
Further Information Favourable Opinion